Ensifentrine

Healio Pulmonology has compiled the top news on COPD posted in 2024.

PHILADELPHIA — To reflect developments in COPD research and care, the 2025 Global Initiative for Chronic Obstructive Lung Disease report features three new sections and several sections that have been updated/revised.

The 2024 GOLD International COPD Conference will be held Nov. 11 and 12 in Philadelphia and online, featuring presentations from various speakers on important topics pertaining to COPD care.

BOSTON — Fewer patients with moderate to severe COPD used health care resources related to the disease if they received ensifentrine for 48 weeks, according to a presentation at the CHEST Annual Meeting.

BOSTON — Lung function, symptoms and quality of life improved with receipt of ensifentrine in both adults with moderate COPD and adults with severe COPD, according to data presented at the CHEST Annual Meeting.

In the first half of 2024, many posts on X, formerly Twitter, from U.S. health care professionals discussing COPD treatments focused on beta-blockers, dupilumab and ensifentrine, according to a tracker from Creation Healthcare.

The FDA has approved the phosphodiesterase enzyme 3 and 4 inhibitor ensifentrine, now named Ohtuvayre, for treating adults with COPD, according to a manufacturer-issued press release.

We are currently experiencing a renaissance in the treatment landscape for respiratory disease, but we can do better.

The FDA is expected to make a decision on ensifentrine to treat patients with COPD by June 26.

During a Midwest Comparative Effectiveness Public Advisory Council public meeting, 11 of 15 members believed current evidence was adequate in showing the net health benefit of ensifentrine plus maintenance therapy.